Prescription medicines transparency measures: Implementation of generic medicines early notification to innovators of an application and publication of innovator application
The submission to the Therapeutic Goods Administration was prepared by the Intellectual Property Committee of the Business Law Section.
The Committee makes the following comments in relation to the consultation regarding ‘Prescription medicines transparency measures: Implementation of generic medicines early notification to innovators of an application and publication of innovator application’ (March 2020).
You can read the full submission below.
Share
Related Documents
Tags
Most recent items in Business Law Section
Business Law Section
Episode Five: Foreign investment reforms: policy and practice
Business Law Section
Externally administered companies: Extending financial reporting and AGM relief
Business Law Section
Increasing the Statutory Demand Threshold
Trending Items in Business Law Section
Business Law Section
Forsyth/Pose Scholarship
Business Law Section
Santow Scholarship
Business Law Section